Very quiet week in the psychedelic market with very little news, but some companies still got…
Category: Mindmed
Psychedelic highlights | June 15-19
Another big week in the psychedelic market. Here is what caught the attention of investors during…
MindMed To Evaluate Ayahuasca’s Active Ingredient DMT In Phase 1 Clinical Trial Collaboration
Phase 1 Trial to experiment with dosing methods to better understand how humans react to DMT,…
MindMed’s Microdosing Division Further Expands Phase 2 Clinical Trial of Microdosing LSD For Adult ADHD
Adds Clinical Trial Site at University Hospital Basel and Appoints World Leading Psychedelics Researcher Dr. Matthias Liechti as…
MindMed Adds MDMA to Develop Next-Gen Psychedelic Therapies
NEW YORK, May 27, 2020 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NEO: MMEDOTCQB: MMEDF), the leading neuro-pharmaceutical…
Mindmed files final prospectus in connection with bought deal equity financing
TORONTO – May 21, 2020 – Mind Medicine (MindMed) Inc. (NEO: MMED, OTCQB: MMEDF) (“MindMed” or the…
MindMed Advances Phase 2 LSD Microdosing Trial For Adult ADHD, Appoints Principal Investigator
Signs Clinical Trial Agreement With Maastricht University In Netherlands TORONTO – May 11, 2020 – Mind Medicine…
From cannabis to psychedelics ?
A psychedelic medical market valued at more than $373 billion Since 2001, the date when medical…
MINDMED ANNOUNCES $10 MILLION BOUGHT DEAL EQUITY FINANCING TO FUND UNIVERSITY HOSPITAL BASEL COLLABORATION
MINDMED ANNOUNCES $10 MILLION BOUGHT DEAL EQUITY FINANCING TO FUND UNIVERSITY HOSPITAL BASEL COLLABORATION NOT FOR…
Psychedelic Pharmaceutical Company MindMed Develops LSD Neutralizer Technology To Shorten and Stop LSD Trips
Advances Discovered in Collaboration with University Hospital Basel’s Liechti Laboratory and Aims To Enhance Therapeutic Potential…
Leading Psychedelic Pharmaceutical Company MindMed Forms New Board Committee To Evaluate Acquisitions And Scientific Collaborations
John Hopkins professor and psychedelics expert Matthew Johnson to act as senior advisor to committee NEW YORK, March 12, 2020 /CNW/…
Mind Medicine Inc goes public on the psychedelics market
Mind Medicine Inc., a psychedelics-based medicine startup closed a $24.2 million funding before to go public…